Table 2.

Numbers needed to treat for the renal outcomes of participants in East and South‐East Asian and non‐East and South‐East Asian countries in Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE)

	NNT for 2.5 years (95% CI)
	EA participants	Non‐EA participants
Primary composite end‐point	13 (8–48)	25 (16–52)
DoSC	13 (8–37)	35 (23–81)
ESKD	15 (9–63)	61 (31–1470)
ESKD, DoSC or renal death	11 (7–30)	37 (23–111)
Dialysis, kidney transplantation or renal death	24 (13–204)	105 †
ESKD, renal death or CV death	18 (9–551)	33 (20–96)

^† 95% confidence interval (CI) for number needed to treat (NNT) is not provided when the 95% CI for absolute risk reduction at 2.5 years includes 0. CV death, cardiovascular death; DoSC, doubling of serum creatinine; EA participants, participants in East and South‐East Asian countries; ESKD, end‐stage kidney disease; non‐EA participants, participants other than East and South‐East Asian participants.